Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study ; volume:37 ; number:9 ; day:9 ; month:7 ; year:2020 ; pages:3775-3790 ; date:9.2020
Advances in therapy ; 37, Heft 9 (9.7.2020), 3775-3790, 9.2020
- Urheber
-
Tabberer, Maggie
Jones, C. Elaine
Kilbride, Sally
Halpin, David M. G.
Lomas, David A.
Pascoe, Steven
Singh, Dave
Wise, Robert A.
Criner, Gerard J.
Lange, Peter
Dransfield, Mark T.
Han, MeiLan K.
Martinez, Fernando J.
Kaisermann, Morrys C.
Lipson, David A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01409-8
- URN
-
urn:nbn:de:101:1-2020100703321047653161
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tabberer, Maggie
- Jones, C. Elaine
- Kilbride, Sally
- Halpin, David M. G.
- Lomas, David A.
- Pascoe, Steven
- Singh, Dave
- Wise, Robert A.
- Criner, Gerard J.
- Lange, Peter
- Dransfield, Mark T.
- Han, MeiLan K.
- Martinez, Fernando J.
- Kaisermann, Morrys C.
- Lipson, David A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials
Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD
Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates
Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study
Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials
Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD
Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates
Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study
Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials
Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD
Inhaler devices in asthma and COPD patients – a prospective cross-sectional study on inhaler preferences and error rates
Inhaler devices in asthma and COPD patients : a prospective cross-sectional study on inhaler preferences and error rates
Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial